Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Bolt Biotherapeutics, a clinical-stage biopharmaceutical company focused on innovative cancer immunotherapies, reported its Q1 2026 financial results and business update. The company is advancing its lead product BDC-4182, a novel immune-stimulating antibody conjugate (ISAC) targeting claudin 18.2 for gastric and gastroesophageal cancers, with init…
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company focused on treating inflammatory diseases such as asthma and COPD, announced its management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference. The company is advancing its lead drug candidate rademikibart, currently in global clini…
High Roller Technologies announced strategic initiatives to launch ROLR-branded prediction markets in the U.S., backed by a definitive agreement with Crypto.com | Derivatives North America, strategic marketing partnerships, and enhanced applied AI capabilities. The company reported Q1 2026 revenues of $3.4 million, improved adjusted EBITDA, reduced…
Reed's, Inc. reported a challenging first quarter of 2026 with net sales declining to $7.1 million from $10 million a year earlier, gross margin compression from 34% to 10%, and a net loss rising to $6.5 million. The company cited inventory rationalization, elevated SG&A expenses, and softer sales execution as key factors impacting results. Leaders…
LB Pharmaceuticals announced Q1 2026 financial results and corporate updates highlighting initiation of pivotal Phase 3 trial for LB-102 in schizophrenia and Phase 2 trial in bipolar depression. The company secured $100 million in a private placement to fund operations into 2029, supporting multiple planned clinical readouts potentially unlocking s…
Mobile Infrastructure Corporation reported Q1 2026 financial results highlighting stable same-location revenue and a 4.4% increase in same-location net operating income (NOI), driven by improved parking utilization and contract volume growth. The company progressed in its $100 million asset rotation program with over $30 million in asset sales, use…
Phillips Edison & Company, a leading US owner and operator of grocery-anchored neighborhood shopping centers, declared monthly dividend distributions of $0.1083 per common share payable in July and August 2026. Additionally, at their virtual annual meeting, all directors were re-elected, executive compensation was approved advisory-wise, and Deloit…
Datadog, Inc., a leading AI-powered observability and security platform, announced that its management team will present at three prestigious investor conferences between May and June 2026. The presentations will be webcast live and later made available on the company's investor relations website.
TELA Bio reported Q1 2026 revenue of $19.1 million, a 3% increase over the previous year, driven by robust international sales and product unit growth. The company launched OviTex LTR in the US, a fully resorbable hernia repair solution, and is expanding its European presence with 41% revenue growth. Despite a net loss increasing slightly to $12.3 …
Reid Alan McWilliams, the Executive Vice President of Global Human Resources at Sanmina Corp (NASDAQ: SANM), executed a sale of company common stock on May 8, 2026. The transaction involved 1,000 shares sold at a price of $248.60 per share, totaling a liquidation value of $248,600. This divestment occurs against a backdrop of significant stock pric…
Jeffrey Zerillo, who serves as the Senior Vice President of Operations at Prestige Consumer Healthcare Inc. (NASDAQ:PBH), has executed a sale of company common stock. The transaction, which took place on May 11, 2026, involved the disposal of 351 shares at a price point of $52.28 per share, resulting in total proceeds of $18,350. Following this div…
Symbotic (SYM) has the ingredients for meaningful revenue conversion over the next 12-18 months: a $22.3B backlog, improving GAAP profitability, and JV and acquisition catalysts. Technical momentum is weak and valuation is premium, but a structured trade with a $51 entry, $45 stop and $70 target balances upside vs execution risk.
Kura Oncology posted $5.8 million in net product revenue from KOMZIFTI in the first full quarter since commercialization, showing strong physician adoption and payer coverage. The company is advancing multiple clinical trials for ziftomenib in AML, with anticipated 2026 data readouts supporting its broad use. The robust cash position and collaborat…
CSX Corporation's Board of Directors has approved a quarterly dividend of $0.14 per share, payable on June 15, 2026, to shareholders of record as of May 29, 2026. CSX is a major transportation company specializing in rail, intermodal, and rail-to-truck transload services across various sectors including energy, industrial, construction, agricultura…
Kyverna Therapeutics announced the initiation of a rolling Biologics License Application (BLA) submission to the FDA for its CAR T-cell therapy, mivocabtagene autoleucel (miv-cel), targeting stiff person syndrome (SPS). The company gained FDA alignment on the regulatory path following a positive pre-BLA meeting. Recent trial data demonstrated robus…
Maze Therapeutics announced positive topline Phase 2 trial data for MZE829 in APOL1-mediated kidney disease (AMKD), demonstrating clinical proof-of-concept and supporting advancement to a pivotal trial. It plans to start Phase 2 trials for MZE782 in phenylketonuria (PKU) and chronic kidney disease (CKD) in 2026, with topline data expected in 2027. …
BIO-key International's Nasdaq-listed shares (BKYI) will be suspended as of May 12, 2026, due to the stock price failing to maintain Nasdaq's $1 minimum bid price for the required duration and delays in filing its annual report. The company will temporarily trade on the OTC Markets while seeking to restore its Nasdaq listing. Despite the suspension…
Nkarta, Inc. reported its Q1 2026 financial results and corporate updates, highlighting progress in its NKX019 clinical trials (Ntrust-1 and Ntrust-2) for autoimmune diseases. The company secured FDA agreement for outpatient dosing, protocol amendments including re-dosing and expanded indications, and obtained multiple IRB approvals. Nkarta maintai…
OptimizeRx Corp. reported Q1 2026 revenue of $19.8 million, a 10% decrease year-on-year, but achieved a narrowed GAAP net loss of $0.5 million and increased adjusted EBITDA to $3.3 million. The company updated its fiscal year 2026 revenue guidance higher to $95-$100 million while maintaining adjusted EBITDA guidance at $21-$25 million. Subsequent t…
Verrica Pharmaceuticals reported a 51.3% year-over-year increase in dispensed YCANTH applicator units and $5.0 million revenue in Q1 2026, highlighting growing adoption of their FDA-approved treatment for molluscum. The company advanced its global Phase 3 trial enrollment for YCANTH's new use in common warts and expanded commercial launch into Japa…
Inhibikase Therapeutics announced the commencement of its pivotal Phase 3 IMPROVE-PAH clinical trial targeting Pulmonary Arterial Hypertension (PAH) with its lead candidate IKT-001. The company secured regulatory approvals across 16 countries including the US and EU, benefiting from the EMA's FAST-EU initiative to expedite trial sites activation. F…
Pacira BioSciences issued a letter to its stockholders ahead of the 2026 Annual Meeting, advocating for votes in favor of its three board nominees. The company emphasizes the nominees' extensive experience in healthcare and biopharmaceutical sectors aligned with Pacira's strategic goals, contrasted against the underqualified nominees proposed by ac…
IZEA Worldwide reported a Q1 2026 revenue of $6.6 million, an 18% decrease year-over-year, reflecting their strategic shift away from low-margin SMB accounts toward higher-value enterprise clients. Despite the revenue decline and a net loss of $0.8 million, the company launched ZED, an AI-powered marketing platform, secured new major clients, and m…
Aura Biosciences, a clinical-stage biotech company specializing in precision therapies for solid tumors, announced that its senior management will participate in two major investor conferences in May 2026 to discuss the company's developments and outlook. Live webcasts will be available and archived on the company's investor relations website.
Scandic Finance Group has introduced SNC Scandic Coin (SNC), a utility token intended for payments, access and loyalty across a range of real-world services inside the group’s ecosystem. Project representatives and documents describe a regulated framework with audited smart contracts, KYC/KYB and AML arrangements, a capped supply and a staged rollo…
